Affymax, a biopharmaceutical company, has appointed Karin Walker, certified public accountant (CPA), as vice president of finance and chief accounting officer (CAO). Walker has over two decades of financial management experience, including in the biotechnology and pharmaceutical industries. In this newly created position she will report to Herb Cross, chief financial officer (CFO), and will be responsible for the strategic and operational leadership of the finance function and accounting activities.
Prior to joining Affymax, Walker served as vice president of finance and corporate controller at Amyris, overseeing all accounting functions during the biotechnology company’s transition from a development-stage company to a commercial organisation. Before joining Amyris in 2009, she was vice president of finance and corporate controller for CV Therapeutics, a biopharmaceutical company, where she built a robust finance function to support corporate growth and a number of complex transactions and strategic initiatives.
Walker has also served in senior financial leadership roles at companies such as Knight Ridder Digital, Accellion and Niku. She earned a BS degree in business from the California State Polytechnic University, San Luis Obispo.
On the second day of this year's AFP conference Trump's potential tax reform, using synthetic debt and the expected benefits of SWIFT GPI were all hotly discussed topics.
Today CGI and GTNews have announced the launch of the fifth annual Transaction Banking survey report, which offers which offers critical insight into the corporate-to-bank relationship.
On-Demand Treasury Management Solutions continue to gain increased adoption in the US and EMEA regions.
Treasurers are being expected to do more work with fewer resources than ever before, so it is little wonder that the automation of day-to-day operations was highly discussed on the second day of EuroFinance, the annual treasury event held in Barcelona this week.